BCHE and Lewy body dementia: Individuals with probable MCI-LB were also more likely to be in receipt of cholinesterase inhibitors at baseline despite comparable cognitive function, consistent with recommendations and their local use in treating neuropsychiatric symptoms of Lewy body disease.19 Due to the observational nature of this study and collinearity with clinical variables, we were limited in our ability to assess the influences of cholinesterase inhibitors in dementia onset; addressing this research question would naturally require a randomized study with larger numbers.